Anavex Life Sciences Analyst Ratings
Anavex Life Sciences Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 603.13% | HC Wainwright & Co. | → $54 | Reiterates | Buy → Buy |
| 07/20/2023 | — | HC Wainwright & Co. | Reiterates | Buy → Buy | |
| 06/29/2023 | 603.13% | HC Wainwright & Co. | → $54 | Reiterates | Buy → Buy |
| 05/02/2023 | 603.13% | HC Wainwright & Co. | → $54 | Reiterates | → Buy |
| 03/31/2023 | 603.13% | HC Wainwright & Co. | $50 → $54 | Maintains | Buy |
| 02/09/2023 | 264.58% | BTIG | $35 → $28 | Maintains | Buy |
| 02/09/2023 | 551.04% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 02/06/2023 | 551.04% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 01/03/2023 | 551.04% | HC Wainwright & Co. | $42 → $50 | Maintains | Buy |
| 12/06/2022 | 43.23% | Cantor Fitzgerald | $16 → $11 | Downgrades | Overweight → Neutral |
| 06/23/2022 | 420.83% | Berenberg | → $40 | Initiates Coverage On | → Buy |
| 02/02/2022 | 446.88% | HC Wainwright & Co. | $39 → $42 | Maintains | Buy |
| 09/23/2021 | 355.73% | BTIG | → $35 | Initiates Coverage On | → Buy |
| 06/28/2021 | 407.81% | HC Wainwright & Co. | $25 → $39 | Maintains | Buy |
| 06/15/2021 | 225.52% | HC Wainwright & Co. | $17 → $25 | Maintains | Buy |
| 02/23/2021 | 225.52% | Cantor Fitzgerald | $10 → $25 | Reiterates | → Overweight |
| 12/16/2020 | 121.35% | HC Wainwright & Co. | $14 → $17 | Maintains | Buy |
| 10/21/2020 | 82.29% | HC Wainwright & Co. | $12 → $14 | Maintains | Buy |
| 09/28/2020 | 56.25% | Ladenburg Thalmann | → $12 | Initiates Coverage On | → Buy |
| 03/16/2020 | 56.25% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 07/24/2019 | 108.33% | Dawson James | → $16 | Initiates Coverage On | → Buy |
| 06/18/2019 | 30.21% | Janney Montgomery Scott | → $10 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023/08/08 | 603.13% | HC Wainwright公司 | →$54 | 重申 | 購買→購買 |
| 07/20/2023 | - | HC Wainwright公司 | 重申 | 購買→購買 | |
| 2023年6月29日 | 603.13% | HC Wainwright公司 | →$54 | 重申 | 購買→購買 |
| 05/02/2023 | 603.13% | HC Wainwright公司 | →$54 | 重申 | →購買 |
| 03/31/2023 | 603.13% | HC Wainwright公司 | $50→$54 | 維護 | 買 |
| 02/09/2023 | 264.58% | BTIG | $35→$28 | 維護 | 買 |
| 02/09/2023 | 551.04% | HC Wainwright公司 | →$50 | 重申 | →購買 |
| 02/06/2023 | 551.04% | HC Wainwright公司 | →$50 | 重申 | →購買 |
| 01/03/2023 | 551.04% | HC Wainwright公司 | $42→$50 | 維護 | 買 |
| 12/06/2022 | 43.23% | 康託·菲茨傑拉德 | $16→$11 | 評級下調 | 超重→中性 |
| 2022/06/23 | 420.83% | 貝倫伯格 | →$40 | 開始承保 | →購買 |
| 02/02/2022 | 446.88% | HC Wainwright公司 | $39→$42 | 維護 | 買 |
| 09/23/2021 | 355.73% | BTIG | →$35 | 開始承保 | →購買 |
| 2021/06/28 | 407.81% | HC Wainwright公司 | $25→$39 | 維護 | 買 |
| 2021/06/15 | 225.52% | HC Wainwright公司 | $17→$25 | 維護 | 買 |
| 02/23/2021 | 225.52% | 康託·菲茨傑拉德 | $10→$25 | 重申 | →超重 |
| 12/16/2020 | 121.35% | HC Wainwright公司 | $14→$17 | 維護 | 買 |
| 10/21/2020 | 82.29% | HC Wainwright公司 | $12→$14 | 維護 | 買 |
| 09/28/2020 | 56.25% | 拉登堡·塔爾曼 | →$12 | 開始承保 | →購買 |
| 03/16/2020 | 56.25% | HC Wainwright公司 | →$12 | 開始承保 | →購買 |
| 2019年07月24日 | 108.33% | 道森·詹姆斯 | →$16 | 開始承保 | →購買 |
| 2019年06月18日 | 30.21% | 詹尼·蒙哥馬利·斯科特 | →$10 | 開始承保 | →購買 |
What is the target price for Anavex Life Sciences (AVXL)?
Anavex Life Science(AVXL)的目標價是多少？
The latest price target for Anavex Life Sciences (NASDAQ: AVXL) was reported by HC Wainwright & Co. on August 8, 2023. The analyst firm set a price target for $54.00 expecting AVXL to rise to within 12 months (a possible 603.13% upside). 10 analyst firms have reported ratings in the last year.
阿納維斯生命科學公司(納斯達克：AVXL)的最新目標價是由HC Wainwright&Co.於2023年8月8日報道的。這家分析公司將目標價定為54美元，預計AVXL將在12個月內上漲至(可能上漲603.13%)。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Anavex Life Sciences (AVXL)?
Anavex Life Science(AVXL)的最新分析師評級是多少？
The latest analyst rating for Anavex Life Sciences (NASDAQ: AVXL) was provided by HC Wainwright & Co., and Anavex Life Sciences reiterated their buy rating.
分析師對Anavex生命科學公司(納斯達克代碼：AVXL)的最新評級由HC Wainwright&Co.提供，Anavex生命科學公司重申其買入評級。
When is the next analyst rating going to be posted or updated for Anavex Life Sciences (AVXL)?
Anavex Life Science(AVXL)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anavex Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anavex Life Sciences was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Anavex生命科學的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Anavex生命科學的上一次評級是在2023年8月8日提交的，因此您應該預計下一次評級將在2024年8月8日左右提供。
Is the Analyst Rating Anavex Life Sciences (AVXL) correct?
分析師對Anavex Life Science(AVXL)的評級正確嗎？
While ratings are subjective and will change, the latest Anavex Life Sciences (AVXL) rating was a reiterated with a price target of $0.00 to $54.00. The current price Anavex Life Sciences (AVXL) is trading at is $7.68, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Anavex生命科學(AVXL)評級被重申，目標價在0.00美元至54.00美元之間。Anavex Life Science(AVXL)目前的交易價格為7.68美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。